| Identification | Back Directory | [Name]
4-HYDROXY-3,3-DIMETHYL-2H-BENZO[G]INDOLE-2,5(3H)-DIONE | [CAS]
39674-97-0 | [Synonyms]
BVT 948
BVT-948
(SPS8I-3)
4-HYDROXY-3,3-DIMETHYL-2H-BENZ[G]INDOLE-2,5(3H)-DIONE
4-HYDROXY-3,3-DIMETHYL-2H-BENZO[G]INDOLE-2,5(3H)-DIONE
2H-Benz[g]indole-2,5(3H)-dione, 4-hydroxy-3,3-dimethyl- | [Molecular Formula]
C14H11NO3 | [MDL Number]
MFCD00616487 | [MOL File]
39674-97-0.mol | [Molecular Weight]
241.24 |
| Chemical Properties | Back Directory | [Boiling point ]
400.8±55.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO: 18 mg/mL
| [form ]
solid
| [pka]
5.78±0.40(Predicted) | [color ]
red
|
| Hazard Information | Back Directory | [Description]
BVT 948 is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTP; IC50s = 0.09-1.7 μM). It facilitates the oxidation of the catalytic cysteine residue by hydrogen peroxide. Similarly, it inhibits redox-sensitive cytochrome P450 (CYP) isoforms, including CYP2C19 and CYP2D6, with IC50 values less than 10 μM. BVT 948 also inhibits the protein methyltransferases SETD8, SETD2, G9a, SMYD2, CARM1, and PRMT3 with IC50 values from 0.7 to 3.2 μm. Presumably through its effects on PTPs, BVT 948 enhances insulin signaling in cells and insulin tolerance in ob/ob mice, suppresses the expression of matrix metalloproteinase-9 and invasion in breast cancer cells, and increases NMDA-induced substance P release by spinal cord slices. | [Uses]
BVT-948 is a noncompetitive cell-permeable inhibitor of tyrosine phosphatases. Helps in the oxidation of the catalytic cysteine residue. May be used as an anti-cancer treatment. | [Biological Activity]
Non-competitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) (IC 50 = 0.09-1.7 μ M); displays irreversible inhibition through catalysis of the hydrogen peroxide-dependent oxidation of PTP. Enhances insulin signaling in vitro and insulin tolerance in ob/ob mice in vivo . Also inhibits several cytochrome P450 isoforms (IC 50 < 10 μ M). | [storage]
Room temperature | [References]
1. liljebris, c., baranczewski, p., bj?rkstrand, e., et al. oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2h-benzo [g]indole-2,5(3h)-dione. j pharmacol exp ther 309(2) 711-719 (2004).2. jallal, b., mossie, k., vasiloudis, g., knyazev, p., zachwieja, j., clairvoyant, f., schilling, j. and ullrich, a. (1997) the receptor-like protein-tyrosine phosphatase dep-1 is constitutively associated with a 64-kda protein serine/threonine kinase. j. biol. chem. 272, 12158-12163.3. wang, f. m., liu, h. q., liu, s. r., tang, s. p., yang, l. and feng, g. s. (2005) shp-2 promoting migration and metastasis of mcf-7 with loss of e-cadherin, dephosphorylation of fak and secretion of mmp-9 induced by il-1 beta in vivo and in vitro. breast cancer res. treat. 89, 5-14.4. hwang bm, chae hs, jeong yj et al.protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9.bmb rep. 2013 nov;46(11):533-8. |
|
|